Details
Stereochemistry | RACEMIC |
Molecular Formula | C24H27N.C6H12O7 |
Molecular Weight | 525.6332 |
Optical Activity | ( + / - ) |
Defined Stereocenters | 4 / 5 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C(O)=O.CC(CC1=CC=CC=C1)NCCC(C2=CC=CC=C2)C3=CC=CC=C3
InChI
InChIKey=XWLQOHKWSBPMOX-IFWQJVLJSA-N
InChI=1S/C24H27N.C6H12O7/c1-20(19-21-11-5-2-6-12-21)25-18-17-24(22-13-7-3-8-14-22)23-15-9-4-10-16-23;7-1-2(8)3(9)4(10)5(11)6(12)13/h2-16,20,24-25H,17-19H2,1H3;2-5,7-11H,1H2,(H,12,13)/t;2-,3-,4+,5-/m.1/s1
Approval Year
Targets
Primary Target | Pharmacology | Condition | Potency |
---|---|---|---|
Target ID: CHEMBL2095229 |
|||
Target ID: CHEMBL1980 Sources: https://www.ncbi.nlm.nih.gov/pubmed/12130695 |
0.72 µM [IC50] | ||
Target ID: CHEMBL6093 Sources: https://www.ncbi.nlm.nih.gov/pubmed/2933041 |
|||
Target ID: Q9H1R3 Gene ID: 85366.0 Gene Symbol: MYLK2 Target Organism: Homo sapiens (Human) Sources: https://www.ncbi.nlm.nih.gov/pubmed/2933041 |
PubMed
Title | Date | PubMed |
---|---|---|
[Prevention of isoproterenol-induced lesions in the rat myocardium by prenylamine]. | 1975 Sep-Oct |
|
Protective effect of creatinol O-phosphate (COP) on ventricular fibrillation and death induced by intravenous CaCl2 in mice. | 1979 |
|
Overdrive pacing in quinidine syncope and other long QT-interval syndromes. | 1980 Aug |
|
An overall review on prenylamine mechanisms of action in experimental models of myocardial damage. | 1982 |
|
Atrio-ventricular block after administration of lignocaine in patients treated with prenylamine. | 1982 Mar |
|
Prevention of adriamycin-induced cardiotoxicity by prenylamine: a pilot double blind study. | 1987 |
|
Female gender as a risk factor for torsades de pointes associated with cardiovascular drugs. | 1993 Dec 1 |
|
[Modulation of serine/threonine protein kinase activity in chloramphenicol-resistant mutants of Streptomyces avermitilis]. | 2004 May-Jun |
|
Comparative evaluation of HERG currents and QT intervals following challenge with suspected torsadogenic and nontorsadogenic drugs. | 2006 Mar |
|
Refining the human iPSC-cardiomyocyte arrhythmic risk assessment model. | 2013 Dec |
Sample Use Guides
In Vivo Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/13978340
270 mg of prenylamine per day for one month
Route of Administration:
Oral
Name | Type | Language | ||
---|---|---|---|---|
|
Common Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Common Name | English |
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
167965
Created by
admin on Sat Dec 16 18:35:02 GMT 2023 , Edited by admin on Sat Dec 16 18:35:02 GMT 2023
|
PRIMARY | |||
|
Q09085O516
Created by
admin on Sat Dec 16 18:35:02 GMT 2023 , Edited by admin on Sat Dec 16 18:35:02 GMT 2023
|
PRIMARY | |||
|
21156-48-9
Created by
admin on Sat Dec 16 18:35:02 GMT 2023 , Edited by admin on Sat Dec 16 18:35:02 GMT 2023
|
PRIMARY | |||
|
DTXSID10943479
Created by
admin on Sat Dec 16 18:35:02 GMT 2023 , Edited by admin on Sat Dec 16 18:35:02 GMT 2023
|
PRIMARY |
SUBSTANCE RECORD